Bremelanotide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Summary

What it does
Bremelanotide raises sexual desire. It is approved in the United States for low sexual desire in women before menopause.
How it works
A peptide given as an injection under the skin of the thigh or abdomen. It switches on melanocortin receptors in the brain that drive arousal, which is a different route from the one erectile-dysfunction pills use.
WADA status
Permitted under World Anti-Doping Agency (WADA) rules. Drug-tested athletes can use it.

Bremelanotide is a therapeutically researched peptide studied for its effects on sexual health, injectable, subcutaneous. Bremelanotide (Vyleesi) is an FDA-approved melanocortin agonist for low sexual desire in premenopausal women; preclinical potential for erectile dysfunction.

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Natty status
Bremelanotide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Mechanism of action
  2. 2 Reported effects
  3. 3 Natty status
  4. 4 Research
  5. 5 Related compounds
  6. 6 References
  7. 7 External links

Mechanism of action

FDA-approved (as Vyleesi) for low sexual desire in premenopausal women. Activates central melanocortin receptors to drive arousal. Shows preclinical promise for erectile dysfunction. Given by subcutaneous injection.

Reported effects

Effects reported in the literature and from preclinical models include:

  • PT-141 shows efficacy for erectile dysfunction through central nervous system activation and nitric oxide regulation. [1] Preclinical
  • PT-141 acts on erectile function through a mechanism distinct from that of PDE5 inhibitors. [1] Preclinical
  • Large-scale clinical trials are still needed to establish PT-141 safety profiles and optimal dosing for erectile dysfunction. [1] Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Natty status

See also: Peptide § Natty status

Bremelanotide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[2]

Research

0 active clinical trials on record . 4 registered in total , of which 4 completed — highest phase ever: Phase 3
View on ClinicalTrials.gov · fetched Sep 4, 2026

The peptide has been the subject of 3 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Melanotan II Not natty
Stimulates melanin production to darken skin and facilitate tanning. May also increase sexual arousal and reduce appetite. Unapproved for human use; linked to nausea and mole changes.
Delta-sleep-inducing peptide Not natty
A neuropeptide named for inducing delta EEG sleep activity in animals, though its own link to human sleep is weak and poorly characterized. Shows preclinical antiepileptic activity.
Epithalon Not natty
Marketed as an anti-aging peptide. In preclinical studies it boosts telomerase activity, supports the body's own melatonin production, and shows antioxidant effects. Human evidence is minimal.
IGF-1 LR3 Not natty
Long-acting IGF-1 analog studied preclinically for muscle growth and tissue repair. No peer-reviewed human evidence of benefit. Risks include hypoglycemia, joint pain, unproven cancer concerns.

References

  1. a b c Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. Recent review
  2. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Sexual health | Injectable | Subcutaneous

This page was last updated on September 4, 2026, at 13:21 (UTC).

Research last reviewed on September 4, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.